title: Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta.
abstract: OBJECTIVE
  Osteogenesis imperfecta (OI) is a hereditary disease causing increased bone fragility. Pamidronate (PAM), which has to be administered as a 3-day course according to the original protocol by Glorieux, is the most frequently used therapy. Other bisphosphonates like neridronate (NER), which can be infused during an outpatient visit, have also proven to be effective. This is the first analysis comparing the effect of PAM and NER using vertebral morphometry.
  
  
  METHODS
  28 patients with OI type III and IV were retrospectively analyzed by matched pairs.
  
  
  RESULTS
  No differences were detected between patients treated with PAM or NER at the start of therapy: mean age 4.4 years (p = 0.730), mean height 86.8 cm/85.3 cm (p = 0.854), lumbar vertebral area 208.9 mm(2)/206.0 mm(2) (p = 0.555), and in all vertebral indices. After 1 year of treatment (mean 1.16 years; p = 0.854) both groups showed a significant increase in the vertebral area and improved vertebral indices. Again there were no differences between the groups in the vertebral area (p = 0.590).
  
  
  CONCLUSIONS
  In this study there was no difference between patients treated with PAM or NER regarding vertebral morphometry during the first year of therapy. Because of the possibility of an outpatient setting, NER is convenient for these children.
authors.affiliation: Children's Hospital, University of Cologne, Cologne, Germany. joerg.semler@uk-koeln.de
authors.forename: O
authors.initials: O
authors.lastname: Semler
authors.forename: R
authors.initials: R
authors.lastname: Beccard
authors.forename: D
authors.initials: D
authors.lastname: Palmisano
authors.forename: A
authors.initials: A
authors.lastname: Demant
authors.forename: O
authors.initials: O
authors.lastname: Fricke
authors.forename: E
authors.initials: E
authors.lastname: Schoenau
authors.forename: F
authors.initials: F
authors.lastname: Koerber
mesh_terms: D015502:Absorptiometry, Photon; D000293:Adolescent; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D016723:Bone Remodeling / Q000187:drug effects*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010013:Osteogenesis Imperfecta / Q000188:drug therapy*; D000077268:Pamidronate; D012189:Retrospective Studies; D013131:Spine / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; C053389:6-amino-1-hydroxyhexane-1,1-diphosphonate; D000077268:Pamidronate